

Benjamin A Fisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9398636/publications.pdf>

Version: 2024-02-01

66
papers

3,630
citations

201674

27
h-index

138484

58
g-index

70
all docs

70
docs citations

70
times ranked

4455
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. <i>Lancet</i> , The, 2022, 399, 161-171.	13.7	72
2	Factors Influencing Surgical Outcomes for Intradural Spinal Tumours: A Single-Centre Retrospective Cohort Study. <i>Cureus</i> , 2022, 14, e21815.	0.5	0
3	Namulumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 255-266.	10.7	32
4	History of tonsillectomy is associated with glandular inflammation in Sjögren's disease. <i>Rheumatology</i> , 2022, , .	1.9	0
5	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 979-989.	0.9	27
6	Immunofibroblasts regulate LT α 3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction. <i>Communications Biology</i> , 2022, 5, 413.	4.4	8
7	Sjögren's and non-Sjögren's sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature. <i>RMD Open</i> , 2022, 8, e002119.	3.8	1
8	Health-related quality of life and costs in Sjögren's syndrome. <i>Rheumatology</i> , 2021, 60, 2588-2601.	1.9	31
9	The management of Sjögren's syndrome: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021, 60, 2122-2127.	1.9	4
10	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. <i>Rheumatology</i> , 2021, 60, 1364-1375.	1.9	26
11	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021, 38, 265-284.	2.7	4
12	Is Image Guidance Essential for External Ventricular Drain Insertion?. <i>World Neurosurgery</i> , 2021, 156, e329-e337.	1.3	3
13	Comment on: Equal rights in autoimmunity: is Sjögren's syndrome ever "secondary"? reply. <i>Rheumatology</i> , 2021, 60, e34-e34.	1.9	0
14	CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults. <i>BMJ Open</i> , 2021, 11, e050202.	1.9	4
15	CXCL13 as biomarker for histological involvement in Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 165-170.	1.9	25
16	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.9	307
17	Is it the end of the road for abatacept treatment in Sjögren's syndrome?. <i>Lancet Rheumatology</i> , The, 2020, 2, e125-e126.	3.9	1
18	Rationale for CD40 pathway blockade in autoimmune rheumatic disorders. <i>Lancet Rheumatology</i> , The, 2020, 2, e292-e301.	3.9	5

#	ARTICLE	IF	CITATIONS
19	Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1588-1599.	0.9	83
20	Equal rights in autoimmunity: is Sjögren's syndrome ever "secondary"? <i>Rheumatology</i> , 2020, 59, 1218-1225.	1.9	40
21	Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. <i>Lancet Rheumatology</i> , The, 2020, 2, e142-e152.	3.9	68
22	A Training Tool to support the management and diagnosis of Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 174-179.	0.8	0
23	Mediterranean diet and risk of Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 216-221.	0.8	4
24	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.	1.6	77
25	Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 13490-13497.	7.1	115
26	AB0458...A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME (PSS). , 2019, , .		1
27	SP0190...2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJÖGREN'S SYNDROME WITH TOPICAL AND SYSTEMIC THERAPIES. , 2019, , .		3
28	Management of rheumatic complications of immune checkpoint inhibitor therapy " an oncological perspective. <i>Rheumatology</i> , 2019, 58, vii29-vii39.	1.9	22
29	Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 249-260.	0.9	33
30	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	5.8	101
31	Response to: Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e28-e28.	0.9	3
32	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 114-122.	0.8	19
33	Subthalamic deep brain stimulation under general anesthesia and neurophysiological guidance while on dopaminergic medication: comparative cohort study. <i>Acta Neurochirurgica</i> , 2018, 160, 823-829.	1.7	7
34	High erythrocyte levels of the n-6 polyunsaturated fatty acid linoleic acid are associated with lower risk of subsequent rheumatoid arthritis in a southern European nested case-control study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 981-987.	0.9	47
35	Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 412-416.	0.9	86
36	Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy. <i>Rheumatology</i> , 2018, 57, 1497-1499.	1.9	6

#	ARTICLE	IF	CITATIONS
37	B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome. <i>Rheumatology</i> , 2018, 57, 1222-1227.	1.9	23
38	Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN- γ secreting cells. <i>Journal of Autoimmunity</i> , 2018, 94, 143-155.	6.5	38
39	High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis. <i>Rheumatology</i> , 2018, 57, 2244-2246.	1.9	29
40	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1161-1168.	0.9	200
41	Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation <i>in Vitro</i> . <i>Journal of Rheumatology</i> , 2017, 44, 748-756.	2.0	22
42	Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability. <i>RMD Open</i> , 2017, 3, e000364.	3.8	87
43	The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. <i>Rheumatology</i> , 2017, 56, e24-e48.	1.9	33
44	The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. <i>Rheumatology</i> , 2017, 56, 1643-1647.	1.9	6
45	A qualitative exploration of physical, mental and ocular fatigue in patients with primary Sjögren's Syndrome. <i>PLoS ONE</i> , 2017, 12, e0187272.	2.5	17
46	Quantitative power Doppler ultrasound measures of peripheral joint synovitis in poor prognosis early rheumatoid arthritis predict radiographic progression. <i>Rheumatology</i> , 2016, 55, 89-93.	1.9	25
47	Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1099-1107.	0.9	125
48	Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1072-1076.	0.8	3
49	Smoking, <i>Porphyromonas gingivalis</i> and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case-control study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 331.	1.9	37
50	A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1645-1650.	0.9	85
51	IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11024-11029.	7.1	173
52	Stratifying primary Sjögren's syndrome: killers in the balance?. <i>Arthritis Research and Therapy</i> , 2015, 17, 351.	3.5	4
53	TNF α regulates cortisol metabolism <i>in vivo</i> in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 464-469.	0.9	17
54	The value of histopathological examination of salivary gland biopsies in diagnosis, prognosis and treatment of Sjögren's Syndrome. <i>Swiss Medical Weekly</i> , 2015, 145, w14168.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Heightened immune response to autocitrullinated <i>Porphyromonas gingivalis</i> peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 263-269.	0.9	171
56	Smoking, the HLA-DRB1 shared epitope and ACPA fine-specificity in Koreans with rheumatoid arthritis: evidence for more than one pathogenic pathway linking smoking to disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 741-747.	0.9	29
57	A1.5...Smoking is a risk factor for ACPA prior to onset of symptoms of rheumatoid arthritis in a cohort from southern europe. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A2.3-A3.	0.9	2
58	The case for measuring antibodies to specific citrullinated antigens. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1185-1192.	3.0	5
59	Autodeimination of <i>Porphyromonas gingivalis</i> peptidylarginine deiminase: a novel antigen in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A26.1-A26.	0.9	1
60	Heterogeneity of Anticitrullinated Peptide Antibodies and Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 929-932.	2.0	20
61	Antibodies to citrullinated Î±-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1095-1098.	0.9	48
62	Reply to "Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis". <i>Nature Genetics</i> , 2010, 42, 816-816.	21.4	1
63	Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. <i>Immunological Reviews</i> , 2010, 233, 34-54.	6.0	407
64	Specific interaction between genotype, smoking and autoimmunity to citrullinated Î±-enolase in the etiology of rheumatoid arthritis. <i>Nature Genetics</i> , 2009, 41, 1319-1324.	21.4	282
65	Prevalence of subjective voice impairment in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008, 27, 1441-1443.	2.2	14
66	Antibodies to citrullinated Î±-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. <i>Arthritis and Rheumatism</i> , 2008, 58, 3009-3019.	6.7	348